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Recently, Yuki et al. published "COVID-19 pathophysiology: A review**"** \[[@bb0005]\]. We read with great interest this article. The authors mentioned that "coagulation dysfunction, thrombosis and pulmonary embolism have been observed in severe COVID-19 \[[@bb0005]\]." We would like to discuss a potential therapeutic strategy to prevent sepsis-induced coagulopathy (SIC) in coronavirus disease 2019 (COVID-19).

The outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread into a pandemic \[[@bb0005]\]. Mortality is high in intensive care unit (ICU), and associated with comorbidities such as diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, or cardiovascular disease \[[@bb0010]\].

COVID-19 is also associated with sepsis-induced coagulopathy (SIC) leading to disseminated intravascular coagulation (DIC) \[[@bb0015]\]. In COVID-19, elevation of D-dimer and fibrin/fibrinogen degradation products are the initial coagulopathy markers found \[[@bb0015]\]. COVID-19 patients also meet Virchow\'s triad criteria for thrombosis: i) endothelial injury, ii) hypercoagulability and iii) venous stasis. Two fibrinolysis markers, D-Dimer and fibrin degradation products, are the hallmarks of SIC-related mortality \[[@bb0015]\].

Low molecular weight heparin (LMWH) is a commonly used anticoagulant to prevent DIC and venous thromboembolism, but its efficiency in DIC remains controversial \[[@bb0015]\]. LMWH also exposes to the risk of heparin induced thrombocytopenia, an immune-mediated syndrome characterized by thrombocytopenia and a high risk for venous or arterial thrombosis \[[@bb0020]\].

Platelets modulate hemostasis and immune responses via interactions with immune cells, through secretion of immune-modulators and cell-cell interactions \[[@bb0025]\]. Platelets activate leukocytes through cell-cell interactions involving adhesion molecules such as P-selectin, a glycoprotein that, upon cell activation, is rapidly translocated from cytoplasmic α-granules to the cell surface \[[@bb0025]\]. Platelets-Leukocytes interactions are important in the pathogenesis of sepsis, and Platelets-Neutrophils Aggregates (PNA) and P-selectin secretion are altered in septic patients \[[@bb0025]\].

The platelet P2Y~12~, a G protein-coupled receptor that are expressed on platelet membranes for adenosine 5'diphosphate (ADP), plays a central role in platelet function, hemostasis, and thrombosis \[[@bb0025]\] ([Fig. 1](#f0005){ref-type="fig"} ). The P2Y~12~ receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders \[[@bb0025]\] such as SIC and DIC.Fig. 1Ticagrelor use to prevent sepsis-induced coagulopathy in COVID-19.(1) SARS-CoV-2 entry into lungs through respiratory droplets.(2) SARS-CoV-2 binds to ACE2 and enters into alveolar (type II) epithelial cell; SARS-CoV-2 replication into alveolar (type II) epithelial cell; Increased inflammation; Increased vascular remodelling; Endothelial dysfunction; Cardiopulmonary dysfunction.(3) Pulmonary arteriole.(4) SARS-CoV-2 binds to ACE2 and enters into endothelial cells; Decreased ACE2; Increased Angiotensin 2; Decreased Angiotensin 1-7; Increased ROS (Reactive Oxygen Species) ; Decreased endothelial NO (Nitric Oxide); Increased endothelial dysfunction; Vascular leakage.(5) Arteriole and blood cells.(6) Thrombus formation in dysfunctional and leaky arteriole; Platelet activation promotes thrombosis; PNA (Platelets-neutrophils aggregates) formation; Ticagrelor inhibits thrombus formation.(7) Platelet activation by ADP binding P2Y12 receptor; PNA (Platelet-Neutrophil Aggregates) formation; NET release by neutrophil; NET contribute to triggering cytokine and ROS release by neutrophil and can alter endothelial barrier, and enhance leakage; Ticagrelor inhibits reversibly P2Y12 receptor and the whole cascade of events described below.Fig. 1

Ticagrelor is an orally administered platelet aggregation inhibitor with a cyclopentyl-triazolopyrimidine structure \[[@bb0025]\] ([Fig. 1](#f0005){ref-type="fig"}). It is a selective reversible P2Y~12~ receptor antagonist, which prevents P2Y~12~-mediated and ADP-mediated platelet activation and aggregation \[[@bb0025]\]. In addition, several studies indicate that ticagrelor may have pleiotropic effects in addition to its anti-platelet properties \[[@bb0030]\].

Here we aim at discussing the potential use of Ticagrelor in COVID-19, to reduce PNA, neutrophil extracellular traps (NETs) release, and vascular leakage.

Ticagrelor was approved for the prevention of severe cardiovascular events among patients with coronary ischemia or ischemic stroke \[[@bb0035]\].

Experimental models of sepsis and human clinical trials have also shown that platelet receptor P2Y12 inhibition reduced sepsis-induced mortality \[[@bb0035], [@bb0040], [@bb0045], [@bb0050]\]. In models of LPS-induced inflammation, Ticagrelor reduced cytokines IL-6, TNF-α, MCP-1 and IL-8 \[[@bb0050]\], and mortality \[[@bb0045]\]. In a model of intra-abdominal sepsis, Ticagrelor reduced sepsis-induced lung injury, neutrophils pulmonary infiltration, PNA formation, platelet activation and thrombocytopenia \[[@bb0040]\].

In the PLATelet inhibition and patient Outcomes (PLATO) study, Ticagrelor reduced mortality risk following pulmonary adverse events such as bacterial lung infection and sepsis in acute coronary syndrome patients \[[@bb0035]\]. According to neutrophils are a first-line defense against bacterial lung infection, a potential mechanism by which ticagrelor could influence host defense against bacterial lung infection is inhibition of cellular uptake of adenosine, a known regulator of neutrophil chemotaxis and phagocytosis \[[@bb0030],[@bb0035]\].

In the human clinical trial "Targeting Platelet-Leukocyte Aggregates in Pneumonia with Ticagrelor (XANTHIPPE) study", Ticagrelor reduced platelet-leucocyte interactions, and IL-6 levels within 24 h in patients with pneumonia \[[@bb0045]\]. It also limited NET release, thus improving lung function, and reducing vascular leakage and oxygen need \[[@bb0045]\]. The findings indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic use of Ticagrelor to reduce complications. Ticagrelor also decreased D-Dimer levels in healthy volunteers \[[@bb0055]\].

One important point in the safe use of Ticagrelor. Pulmonary hemorrhage has been reported under dual antiplatelet therapy: Ticagrelor plus aspirin \[[@bb0060]\]. To avoid an increased bleeding risk, randomized controlled trial showed a net benefit of aspirin-free antiplatelet therapy \[[@bb0065]\]. This was demonstrated in the XANTHIPPE study, since Ticagrelor use was safe with no major bleeding reported \[[@bb0045]\].

COVID-19 is associated with coagulopathy through ([Fig. 1](#f0005){ref-type="fig"}): i) endothelial injury/dysfunction induced by the binding of SARS-CoV-2 to endothelial ACE2 receptor that leads to excess thrombin generation and fibrinolysis \[[@bb0070]\]; ii) platelet activation that induces hypercoagulability and membrane receptor expression enabling PNA between platelets and leukocytes \[[@bb0075]\]; iii) PNA formation that release pro-inflammatory cytokines, reactive oxygen species and NETs; iv) NETs released from activated neutrophils in response to infection such as SARS-CoV-2 can trap, and kill microorganisms \[[@bb0075]\]. They also activate platelets and coagulation, and contribute to thrombogenesis by forming a mesh with platelets and fibrin and accumulating coagulation factors such as Tissue Factor; v) Inflammation induced by NET-components (DNA, histone, and granule proteins including proteases such as elastase and pro-oxidant enzymes such as myeloperoxidase) also contribute to triggering cytokine release, oxidative stress and extracellular matrix proteolysis \[[@bb0075]\].

Cytokines and reactive oxygen species released by neutrophils can alter the endothelial barrier function, enhance leakage, and promote the development of tissue oedema and hypoxia \[[@bb0075]\] leading to acute respiratory distress and multiple organ dysfunction \[[@bb0070]\].

Therefore, when given at the early onset of COVID-19, Ticagrelor, through inhibition of platelet-neutrophil aggregates, NET release, and vascular leakage might prevent SIC, progression to DIC and associated morbi/mortality in COVID-19 patients. Ticagrelor could be a promised candidate to prevent SIC that it would be interesting to evaluate in a randomized clinical trial in COVID-19.
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